GLPcompareGLPcompare
DrugsPricesCompareShortagesEvidenceSupplementsWatchlist
HomeDrugsSurvodutide
GLP-1/glucagonInvestigational · Phase 3

Survodutide

Dual glucagon and GLP-1 receptor agonist. Once weekly.

Survodutide (investigational)·Boehringer Ingelheim / Zealand Pharma

Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.

OverviewDosing & warningsClinical trials

What to know about Survodutide

An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.

Mean weight change in the cited trial
−16.6% (-16.6% at 76 wks · SYNCHRONIZE-1 (Phase 3) · 6.0 mg weekly (Phase 3))

SYNCHRONIZE-1 (Phase 3) · 6.0 mg weekly (Phase 3)

Stopped treatment for adverse events
24.8% (24.8% stopped the drug vs 5.4% placebo (6.0 mg) · SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity))

SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity)

FDA shortage report
In development

Investigational. Not FDA-approved.

Route & frequency
Once weekly

Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.

Indications

Investigational uses

Survodutide (investigational)

Obesity; MASH (investigational)

Obesity (investigational)MASH / liver disease (investigational)

An investigational dual glucagon/GLP-1 receptor agonist; the glucagon component is being studied for effects on liver fat and metabolism.

Product labeling

Dosing, warnings & contraindications

Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.

No approved label (investigational)

Survodutide is investigational. See its registered studies below. Search DailyMed.

Source: submitted product labeling via openFDA. A listing does not establish FDA approval and may differ from current approved labeling. Read the current prescribing information and consult a clinician.
Tolerability

Side effects reported in the trial

Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.

Discontinued for side effects

24.8% (24.8% stopped the drug vs 5.4% placebo (6.0 mg) · SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity))

Reported as 24.8% stopped the drug vs 5.4% placebo (6.0 mg). The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.

Had nausea

64.9% (Nausea in the drug arm · SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity))

The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.

GI events (nausea 65%, vomiting 45%, diarrhea 40%) affected ~90% of the 6.0 mg arm, the highest GI burden of the class, mostly mild-to-moderate and during dose escalation.

From SYNCHRONIZE-1 (6.0 mg, 76 wks, obesity) (24.8% is the rate that stopped the study drug; only 1.7% left the trial entirely (the treatment-regimen estimand keeps them in follow-up), so it is not one-to-one with an all-cause dropout rate). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source.

Evidence

Clinical trials

29 registered trials indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.

  • A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
    NCT04667377PHASE2Completed387 enrolled
    Has results
    Primary outcome: Percentage Change in Body Weight From Baseline to Week 46

    Selected primary outcome

    Results · Sep 25, 2026 UTC

    Percentage Change in Body Weight From Baseline to Week 46

    Least-squares mean · Percentage change · Baseline, Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46.

    Analysis population: Full analysis set (all randomised participants who received at least one dose of study treatment and who have analysable data for at least one efficacy endpoint) using planned maintenance treatment. Number of participants analysed = Participants with available data for the outcome measure.

Related

Related GLP-1s to compare

Semaglutide
Ozempic, Wegovy, Wegovy HD, Rybelsus
Tirzepatide
Mounjaro, Zepbound
Liraglutide
Victoza, Saxenda
Orforglipron
Foundayo
Questions

Common questions about Survodutide

How much weight can you lose on Survodutide?
In its pivotal trial (SYNCHRONIZE-1 (Phase 3)), Survodutide at 6.0 mg weekly (Phase 3) showed a mean body-weight change of -16.6% at 76 wks. This is a trial average; individual results vary. Source
Is Survodutide available yet?
No. Survodutide is investigational (Phase 3) and not FDA-approved, so it cannot be prescribed or bought yet.
All shortagesPrice comparisonCompare drugsProvidersEvidence hubMethodology
GLPcompareGLPcompare

The live, fully-cited reference for the GLP-1 ecosystem. Every figure traces to its source. Informational only, not medical advice.

Product

  • Drugs
  • Prices
  • Compare
  • Shortages
  • Evidence
  • Supplements

Legal

  • Methodology
  • About
  • News
  • Price updates
  • Privacy Policy
  • Terms of Service
  • Support

Some outbound links on GLPcompare are referral links. If you sign up or buy through one, we may earn a commission at no extra cost to you. It never changes the price you pay or the underlying data. Partner status and commission rates contribute to offer and provider value scores and can change their order. Every partner is labeled. Value scores are not medical recommendations; a higher-ranked offer is not necessarily the lowest price or the right product for you.

© 2026 GLPcompare. All rights reserved.

Fazier
0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation)
-6.19 Percentage change

Standard Error: 1.07

Overall outcome: 76 Participants analyzed

2.4 mg BI 456906 - Planned Maintenance Treatment
-12.51 Percentage change

Standard Error: 1.01

Overall outcome: 78 Participants analyzed

3.6 mg BI 456906 - Planned Maintenance Treatment
-13.22 Percentage change

Standard Error: 1.04

Overall outcome: 76 Participants analyzed

4.8 mg BI 456906 - Planned Maintenance Treatment
-14.94 Percentage change

Standard Error: 1.01

Overall outcome: 76 Participants analyzed

Placebo
-2.82 Percentage change

Standard Error: 1.06

Overall outcome: 77 Participants analyzed

Outcome definition & treatment groups

Percentage change in body weight from baseline to Week 46 was modeled using a mixed model for repeated measures (MMRM) with fixed effects for baseline body weight as a continuous linear covariate, and treatment, gender, visit, treatment by visit interaction and baseline by visit interaction as factors, using visit (Week 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 24, 28, 32, 36, 40, and 46) as repeated measures, an unstructured covariance matrix to model within subject measurements, adjusted mean (standard error) at Week 46 is reported. For analysis, all available post-baseline body weight measurements (on- and off-treatment) were used, except those for participants who discontinued treatment early due to COVID-19. For these participants only on-treatment values were used. That is, a hypothetical strategy was used for intercurrent event (ICE) "COVID-19 pandemic-related early treatment discontinuation", a treatment policy strategy for ICE "non-pandemic-related early treatment discontinuation".

0.6 mg BI 456906 - Planned Maintenance Treatment (Maintenance Dose Assigned at Randomisation): Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and 2, and 0.6 mg on Week 3 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 0.6 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

2.4 mg BI 456906 - Planned Maintenance Treatment: Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and Week 2, 0.6 mg on Week 3 and Week 4, 0.9 mg on Week 5 and Week 6, 1.2 mg on Week 7 to Week 10, 1.8 mg on Week 11 to Week 14 and 2.4 mg on Week 15 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 2.4 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

3.6 mg BI 456906 - Planned Maintenance Treatment: Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and Week 2, 0.6 mg on Week 3 and Week 4, 0.9 mg on Week 5 and Week 6, 1.2 mg on Week 7 to Week 10, 1.8 mg on Week 11 and Week 12, 2.4 mg on Week 13 and Week 14, 3.0 mg on Week 15 and Week 16, and 3.6 mg on Week 17 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 3.6 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

4.8 mg BI 456906 - Planned Maintenance Treatment: Participants with obesity or overweight were administered a solution for injection of BI 456906, by a weekly subcutaneous injection of two syringes (0.5 mL filling volume per syringe) on the same injection day, of 0.3 mg on Week 1 and Week 2, 0.6 mg on Week 3 and Week 4, 0.9 mg on Week 5 and Week 6, 1.2 mg on Week 7 and Week 8, 1.8 mg on Week 9 and Week 10, 2.4 mg on Week 11 and Week 12, 3.3 mg on Week 13 and Week 14, 4.2 mg on Week 15 and Week 16, and 4.8 mg on Week 17 to Week 20 (dose escalation phase, with fixed dose escalation from Week 1 to Week 10 and flexible dose escalation from Week 11 to Week 20). From Week 21 to Week 46 (maintenance dosing phase) participants stayed on the dose of 4.8 mg BI 456906. Participant not tolerating the assigned dose escalation schedule due to gastrointestinal adverse events had the option of dose adjustment during the flexible part of the dose escalation phase (Week 11 - 20) which could lead to a maintenance dose lower than the dose the participant was randomised to.

Placebo: Participants with obesity or overweight were administered a solution for injection of Placebo, by a weekly subcutaneous injection of two syringes on the same injection day, for 46 weeks.

One of 1 registered primary outcome, selected for its reported data and weight or blood-sugar endpoint where available. These are registry values; published analyses may differ. Full results on ClinicalTrials.gov.

  • A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™…
    NCT06077864PHASE3Completed5,531 enrolled
  • LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced…
    NCT06632444PHASE3Recruiting1,800 enrolled
  • LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
    NCT06632457PHASE3Recruiting1,590 enrolled
  • A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose…
    NCT06066528PHASE3Completed755 enrolled
  • A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose…
    NCT06066515PHASE3Completed726 enrolled
  • SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going…
    NCT07850050PHASE3Not_yet_recruiting600 enrolled
  • ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or…
    NCT07850063PHASE3Not_yet_recruiting600 enrolled
  • A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
    NCT07754461PHASE3Recruiting600 enrolled
  • SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes…
    NCT07855900PHASE3Not_yet_recruiting350 enrolled
  • A Study to Test Whether Survodutide (BI 456906) Helps Chinese People Living With Overweight or Obesity to Lose Weight
    NCT06214741PHASE3Completed307 enrolled
  • A Study to Test Whether Survodutide Helps Japanese People Living With Obesity Disease
    NCT06176365PHASE3Completed274 enrolled

    • Source: ClinicalTrials.gov API v2 · as of Oct 3, 2026

    All trials on ClinicalTrials.gov